Free Trial
NASDAQ:CORV

Correvio Pharma (CORV) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.42
$0.42
50-Day Range
$0.39
$0.42
52-Week Range
$0.21
$2.79
Volume
N/A
Average Volume
5.35 million shs
Market Capitalization
$27.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Correvio Pharma

Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.

CORV Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Big Pharma Split Corp Class A
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Nutra Pharma Corp. (NPHC)
Protect Pharmaceutical Corp.
Stella Pharma Corp Ordinary Shares 4888
See More Headlines
Receive CORV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Correvio Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/30/2020
Today
7/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CORV
CIK
N/A
Fax
N/A
Employees
133
Year Founded
N/A

Profitability

Net Income
$-35,180,000.00
Net Margins
-107.81%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$32.63 million
Book Value
($0.02) per share

Miscellaneous

Free Float
N/A
Market Cap
$27.80 million
Optionable
Optionable
Beta
0.08
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Mark H. N. Corrigan (Age 62)
    CEO & Director
  • Mr. Justin A. Renz CPA (Age 48)
    MST, M.S.T., MBA, CFO & Pres
  • Ms. Sheila M. Grant
    Chief Operating Officer
  • Mr. David D. McMasters (Age 61)
    Chief Compliance Officer & Gen. Counsel
  • Mr. Hugues Sachot
    Chief Commercial Officer

CORV Stock Analysis - Frequently Asked Questions

How were Correvio Pharma's earnings last quarter?

Correvio Pharma Corp (NASDAQ:CORV) released its quarterly earnings results on Monday, March, 30th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. The business had revenue of $11.33 million for the quarter, compared to analysts' expectations of $11.52 million. Correvio Pharma had a negative net margin of 107.81% and a negative trailing twelve-month return on equity of 2,128.82%.

What other stocks do shareholders of Correvio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Correvio Pharma investors own include Inovio Pharmaceuticals (INO), Outlook Therapeutics (OTLK), SCYNEXIS (SCYX), Heat Biologics (HTBX), Actinium Pharmaceuticals (ATNM), Acasti Pharma (ACST) and Biocept (BIOC).

This page (NASDAQ:CORV) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners